小児用医薬品の世界市場レポート 2025年

小児用医薬品市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）14.9％で3,160億米ドルに成長します。予測期間の成長は、小児人口の増加、小児精神衛生問題の有病率の上昇、慢性疾患を抱える小児数の増加、ワクチン接種率の上昇、小児精神衛生薬の需要増に起因すると考えられます。主な動向としては、個別化小児医療の台頭、小児ドラッグデリバリーの技術進歩、遠隔医療とデジタルヘルスソリューションの拡大、小児臨床試験の強化、小児科医と薬剤師の連携強化などが挙げられます。

早産児の増加は、今後数年間の小児用医薬品市場の成長を促進すると予想されます。早産とは、一般的な妊娠40週よりも早い妊娠37週未満に生まれた乳児のことです。早産の増加には、母親の年齢上昇、ライフスタイルの選択、病状、多胎妊娠、不十分な妊婦ケアなど、いくつかの要因があります。小児用医薬品は、呼吸器合併症、感染症、栄養不足などの課題に取り組むことで、早産児の健康と開発を支援する上で重要な役割を担っています。例えば、2022年12月、英国を拠点とする慈善団体Tommy'sが発表した報告書によると、イングランドとウェールズにおける早産児の割合は、2021年の7.5％から2022年には7.9％に増加しました。この上昇により、2022年に早産で生まれた赤ちゃんは5万3,000人を超えました。その結果、早産児の増加が小児用医薬品市場の拡大に拍車をかけています。

小児用医薬品市場の主要企業は、完全ヒト型モノクローナル抗体などの革新的治療法の開発に注力し、若年患者の治療成績の向上と副作用の軽減を図っています。完全ヒト型モノクローナル抗体（mAb）は、キメラ抗体やヒト化モノクローナル抗体と比較して、免疫反応のリスクを最小限に抑えることができる、完全にヒトの遺伝子配列に由来する抗体です。これらの抗体は、ヒト抗体遺伝子を導入したトランスジェニックマウスやファージディスプレイ技術などの高度なバイオテクノロジー技術を用いて製造されます。例えば、2022年8月、米国の製薬会社ジョンソン・エンド・ジョンソンは、6歳以上の活動性乾癬性関節炎（PsA）小児患者の治療薬としてステララ（ウステキヌマブ）のFDA承認を取得しました。STELARAは、自己免疫疾患に伴う炎症反応に重要な役割を果たすサイトカインであるインターロイキン-12（IL-12）とインターロイキン-23（IL-23）を標的とする最初で唯一の生物学的製剤であり、この承認は重要なブレークスルーとなりました。活動性PsAは、小児の慢性炎症性関節炎の約5～8％が罹患するまれな疾患で、関節の腫脹や皮膚病変などの症状を引き起こします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界小児用医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の小児用医薬品市場：成長率分析
• 世界の小児用医薬品市場の実績：規模と成長, 2019-2024
• 世界の小児用医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界小児用医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の小児用医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 呼吸器疾患治療薬
• 自己免疫疾患治療薬
• 胃腸薬
• 心血管薬
• 世界の小児用医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• トピック
• 非経口
• その他の投与経路
• 世界の小児用医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の小児用医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の小児用医薬品市場呼吸器疾患治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息の薬
• 嚢胞性線維症の治療
• 気管支拡張薬
• コルチコステロイド
• 世界の小児用医薬品市場自己免疫疾患治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 生物学的療法
• 疾患修飾抗リウマチ薬（DMARD）
• 世界の小児用医薬品市場消化器系薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトンポンプ阻害剤（PPI）
• 制吐剤
• 下痢止め
• 下剤
• 世界の小児用医薬品市場心血管薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 降圧薬
• 心不全の治療
• 抗不整脈薬
• 脂質低下剤

第7章 地域別・国別分析

• 世界の小児用医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の小児用医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 小児用医薬品市場：競合情勢
• 小児用医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• AstraZeneca Plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Eli Lilly and Co.
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Vertex Pharmaceuticals
• UCB Pharma
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company
• Shionogi & Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 小児用医薬品市場2029：新たな機会を提供する国
• 小児用医薬品市場2029：新たな機会を提供するセグメント
• 小児用医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pediatric drugs are medications specifically formulated, dosed, and approved for use in infants, children, and adolescents. These drugs are designed to treat a wide range of medical conditions in pediatric patients, taking into account their unique physiological and metabolic differences from adults.

The primary types of pediatric drugs include respiratory disorder drugs, autoimmune disorder drugs, gastrointestinal drugs, and cardiovascular drugs. Respiratory disorder drugs are formulated to manage breathing-related conditions in children, such as asthma, cystic fibrosis, and respiratory syncytial virus (RSV). These medications can be administered through various routes, including oral, topical, and parenteral methods. They are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. Pediatric drugs are utilized by various end users, including hospitals, specialty clinics, homecare settings, and other healthcare facilities.

The pediatric drugs market research report is one of a series of new reports from The Business Research Company that provides pediatric drugs market statistics, including the pediatric drugs industry global market size, regional shares, competitors with the pediatric drugs market share, detailed pediatric drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pediatric drugs industry. This pediatric drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pediatric drugs market size has grown rapidly in recent years. It will grow from $157.0 billion in 2024 to $181.02 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to the rising demand for pediatric medications, a growing pediatric population, increased awareness of pediatric diseases, the expansion of pediatric oncology, the rise of digital health and telemedicine, and enhanced collaboration in pediatric drug development.

The pediatric drugs market size is expected to see rapid growth in the next few years. It will grow to $316.0 billion in 2029 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to an increasing pediatric population, a rising prevalence of pediatric mental health issues, a growing number of children with chronic conditions, higher vaccination rates, and increasing demand for pediatric mental health medications. Major trends include the rise of personalized pediatric medicine, technological advancements in pediatric drug delivery, the expansion of telemedicine and digital health solutions, enhanced pediatric clinical trials, and increased collaboration between pediatricians and pharmacists.

The increasing number of preterm births is anticipated to drive the growth of the pediatric drugs market in the coming years. Preterm births refer to infants born before completing 37 weeks of gestation, which is earlier than the typical 40-week term. Several factors contribute to the rise in preterm births, including increased maternal age, lifestyle choices, medical conditions, multiple pregnancies, and inadequate prenatal care. Pediatric drugs play a crucial role in supporting the health and development of preterm infants by addressing challenges such as respiratory complications, infections, and nutritional deficiencies. For example, in December 2022, a report published by Tommy's, a UK-based charity organization, indicated that the percentage of premature live births in England and Wales increased to 7.9% in 2022, up from 7.5% in 2021. This rise accounted for more than 53,000 babies born prematurely in 2022. As a result, the growing number of preterm births is fueling the expansion of the pediatric drugs market.

Leading companies in the pediatric drugs market are focusing on developing innovative treatments, such as fully human monoclonal antibodies, to enhance therapeutic outcomes and reduce side effects for young patients. A fully human monoclonal antibody (mAb) is derived entirely from human genetic sequences, minimizing the risk of immune reactions compared to chimeric or humanized monoclonal antibodies. These antibodies are produced using advanced biotechnological techniques, such as transgenic mice with human antibody genes or phage display technology. For instance, in August 2022, Johnson & Johnson, a US-based pharmaceutical company, received FDA approval for STELARA (ustekinumab) to treat pediatric patients aged six years and older with active psoriatic arthritis (PsA). This approval marked a significant breakthrough, as STELARA is the first and only biologic therapy targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that play a key role in the inflammatory responses associated with autoimmune diseases. Active PsA is a rare condition that affects approximately 5-8% of children with chronic inflammatory arthritis, causing symptoms such as joint swelling and skin lesions.

In July 2022, JB Chemicals & Pharma Limited, an India-based pharmaceutical company, acquired four pediatric brands from Dr. Reddy's Laboratories for ₹98.3 crore (approximately $1.18 million). This acquisition was aimed at expanding JB Pharma's presence in the pediatric segment by leveraging the market leadership of the acquired brands to strengthen its portfolio and support future growth ambitions in India. Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company specializing in pediatric drug development.

Major players in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila.

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pediatric drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pediatric drugs market consists of sales of antibiotics, vaccines, pediatric pain relief, respiratory medications, antihistamines, and pediatric dermatology products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pediatric Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pediatric drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pediatric drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pediatric drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Respiratory Disorder Drugs; Autoimmune Disorder Drugs; Gastrointestinal Drugs; Cardiovascular Drugs
• 2) By Route Of Administration: Oral; Topical; Parenteral; Other Route Of Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Respiratory Disorder Drugs: Asthma Medications; Cystic Fibrosis Treatments; Bronchodilators; Corticosteroids
• 2) By Autoimmune Disorder Drugs: Immunosuppressants; Biologic Therapies; Disease-Modifying Antirheumatic Drugs (DMARDs)
• 3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs); Antiemetics; Antidiarrheals; Laxatives
• 4) By Cardiovascular Drugs: Antihypertensive Medications; Heart Failure Treatments; Antiarrhythmic Drugs; Lipid-lowering Agents
• Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pediatric Drugs Market Characteristics

3. Pediatric Drugs Market Trends And Strategies

4. Pediatric Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pediatric Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pediatric Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pediatric Drugs Market Growth Rate Analysis
• 5.4. Global Pediatric Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pediatric Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pediatric Drugs Total Addressable Market (TAM)

6. Pediatric Drugs Market Segmentation

• 6.1. Global Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Disorder Drugs
• Autoimmune Disorder Drugs
• Gastrointestinal Drugs
• Cardiovascular Drugs
• 6.2. Global Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• Parenteral
• Other Route Of Administrations
• 6.3. Global Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.4. Global Pediatric Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Pediatric Drugs Market, Sub-Segmentation Of Respiratory Disorder Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma Medications
• Cystic Fibrosis Treatments
• Bronchodilators
• Corticosteroids
• 6.6. Global Pediatric Drugs Market, Sub-Segmentation Of Autoimmune Disorder Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Biologic Therapies
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• 6.7. Global Pediatric Drugs Market, Sub-Segmentation Of Gastrointestinal Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPIs)
• Antiemetics
• Antidiarrheals
• Laxatives
• 6.8. Global Pediatric Drugs Market, Sub-Segmentation Of Cardiovascular Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihypertensive Medications
• Heart Failure Treatments
• Antiarrhythmic Drugs
• Lipid-lowering Agents

7. Pediatric Drugs Market Regional And Country Analysis

• 7.1. Global Pediatric Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pediatric Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pediatric Drugs Market

• 8.1. Asia-Pacific Pediatric Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pediatric Drugs Market

• 9.1. China Pediatric Drugs Market Overview
• 9.2. China Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pediatric Drugs Market

• 10.1. India Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pediatric Drugs Market

• 11.1. Japan Pediatric Drugs Market Overview
• 11.2. Japan Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pediatric Drugs Market

• 12.1. Australia Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pediatric Drugs Market

• 13.1. Indonesia Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pediatric Drugs Market

• 14.1. South Korea Pediatric Drugs Market Overview
• 14.2. South Korea Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pediatric Drugs Market

• 15.1. Western Europe Pediatric Drugs Market Overview
• 15.2. Western Europe Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pediatric Drugs Market

• 16.1. UK Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pediatric Drugs Market

• 17.1. Germany Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pediatric Drugs Market

• 18.1. France Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pediatric Drugs Market

• 19.1. Italy Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pediatric Drugs Market

• 20.1. Spain Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pediatric Drugs Market

• 21.1. Eastern Europe Pediatric Drugs Market Overview
• 21.2. Eastern Europe Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pediatric Drugs Market

• 22.1. Russia Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pediatric Drugs Market

• 23.1. North America Pediatric Drugs Market Overview
• 23.2. North America Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pediatric Drugs Market

• 24.1. USA Pediatric Drugs Market Overview
• 24.2. USA Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pediatric Drugs Market

• 25.1. Canada Pediatric Drugs Market Overview
• 25.2. Canada Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pediatric Drugs Market

• 26.1. South America Pediatric Drugs Market Overview
• 26.2. South America Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pediatric Drugs Market

• 27.1. Brazil Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pediatric Drugs Market

• 28.1. Middle East Pediatric Drugs Market Overview
• 28.2. Middle East Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pediatric Drugs Market

• 29.1. Africa Pediatric Drugs Market Overview
• 29.2. Africa Pediatric Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pediatric Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pediatric Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pediatric Drugs Market Competitive Landscape And Company Profiles

• 30.1. Pediatric Drugs Market Competitive Landscape
• 30.2. Pediatric Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Pediatric Drugs Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. AstraZeneca Plc
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company
• 31.6. Eli Lilly and Co.
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Vertex Pharmaceuticals
• 31.12. UCB Pharma
• 31.13. Sun Pharmaceutical Industries Ltd.
• 31.14. Perrigo Company
• 31.15. Shionogi & Co. Ltd.

32. Global Pediatric Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pediatric Drugs Market

34. Recent Developments In The Pediatric Drugs Market

35. Pediatric Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Pediatric Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pediatric Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pediatric Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer